AbGenics Lifesciences

Antibody discovery company working in 3 different formats, Camelid heavy chain fragments (VHH), Human scfv and mouse scfv. Antibody fragment libraries against infectious diseases and cancers have been used to isolate hits that have been further developed for therapeutic and diagnostic applications. Developing two new technologies, VHH-Antimicrobial peptide conjugates called AbTids to control the AMR problem and an ultrasensitive diagnostic test, CabPath for detection of blood borne pathogens in sepsis patients, particularly in neonates

Biotech,pharma,microbiology,cancer,molecular biology ,antibody engineering,non traditional antimicrobials,antimicrobial peptides,diagnostics,human health,and animal health

Abgenics lifesciences operates in the Research industry.

Abgenics lifesciences's revenue is 11m - 100m

Abgenics lifesciences has 11 - 50 employees.